Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics (Premium)
$10.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Astellas Pharma Inc Announces Approval of Prograf Capsules in Japan for Additional Indication of Interstitial Pneumonia Associated with Polymyositis /Dermatomyositis


Friday, 14 Jun 2013 02:00am EDT 

Astellas Pharma Inc announced on June 13, 2013 that it has been granted approval in Japan for the additional indication of interstitial pneumonia associated with polymyositis/dermatomyositis for Prograf capsules 0.5mg, 1.0mg (generic name: tacrolimus hydrate). Tacrolimus is an immunosuppressant discovered and developed by Astellas. The capsule formulation of tacrolimus is marketed as an immunosuppressant for organ transplantation etc. under the brand name "Prograf" etc. in 99* countries/areas. In Japan, Prograf was also approved for myasthenia gravis, rheumatoid arthritis, lupus nephritis and ulcerative colitis. 

Company Quote

1495.5
-1.0 -0.07%
20 Aug 2014